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Cardiac troponin I (cTnI) is a sensitive and reliable marker
of myocardial damage, and it can be used to diagnose acute
coronary syndrome [1,2]. Because therapeutic decisions
may be made based on relatively small increases in cTnI,
troponin assays must have high sensitivity and specificity.
The molecular complexity of cTnI causes discrepancies
in its measurement by different assays [3]. In addition,
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Cardiac troponin I (cTnI) has been found to be a sensitive and reliable marker of myocardial damage, and
elevated levels of cTnI can indicate high risk for acute coronary syndrome. To determine how to intervene
in possible cases of acute coronary syndrome, cTnI levels must be measured by immunoassay. However,
cTnI immunoassay results are prone to interference from many substances such as heparin and common
drugs. The contrast media used in the coronary angiography might also interfere with results. To explore this
possibility, we performed two in vivo and two in vitro studies. In the first in vivo study, we evaluated the
effects of contrast media on cTnI immunoassays by collecting blood samples from 45 patients undergoing
coronary angiography before and after the procedure. We used the Opus Magnum immunoassay system to
measure cTnI levels. In the second in vivo study, we collected 25 blood samples from another group of
patients also undergoing angiography at various times before and after the procedure to determine cTnI
values by both the Opus Magnum and ACCESS systems. In the first in vitro study, 12 different contrast media
were treated as samples to disclose the potential interference of measurement in the two assay systems. In
the second in vitro study, we made sequential dilutions of iopromide (Ultravist; Schering) with serum to
explore their potential for interfering with the detection of cTnI by the Opus Magnum and ACCESS assays.
In the first in vivo study using the Opus Magnum assay, cTnI concentrations in samples taken after
angiography were significantly higher at 5 minutes than at 30 minutes, and, at 60 minutes, all cTnI
concentrations had dropped below the cutoff point. In the second in vivo study, we found a substantial
difference in detection of cTnI by the Opus Magnum and ACCESS assays. All cTnI concentrations checked
by ACCESS assay were below the cutoff value. In our first in vitro study, the Opus Magnum assay gave false
positive results for all 12 contrast media; the ACCESS assay gave a positive result for only one contrast
medium, poppy-seed oil (Lipiodol; Guebert). In our second in vitro study, we found that, in the Opus
Magnum assay, the more concentrated the contrast medium, the higher the cTnI value, but not in the
ACCESS assay. We conclude that contrast media may cause false-positive results in cTnI assays and that,
when contrast media are being used for angiography, cTnI results, especially those based on samples taken
within the first hour of the procedure, should be interpreted carefully.
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because the immunoassays measuring cTnI use an array of
various antibodies, the assays are prone to interference,
which has been reported to occur with the use of heparin,
blood constituents, hemolysis, bilirubin, common drugs,
heterophilic antibodies, human anti-mouse antibodies, and
rheumatoid factors [4–6].
Contrast media are essential for all radiologic
angiographies, including coronary angiography, and are
also essential for percutaneous coronary intervention.
Although cardiac damage can be practically and sensitively
detected after percutaneous coronary intervention by
measuring cTnI, few clinicians know that commercial assays
of troponin are prone to interference [4–6]. Because it was
not known whether contrast media can interfere with
immunoassay for cTnI, we used two in vivo and two in vitro
studies to observe the effects of various contrast media on
the results of two cTnI immunoassays: the Opus Magnum
immunoassay and the ACCESS immunoassay.
MATERIALS AND METHODS
cTnI Measurement
cTnI concentrations were measured using two automatic
commercial  assays:  Opus Magnum (Opus cTnI
immunoassay system; Behring Diagnostics) and ACCESS
cTnI immunoassay; Beckman Coulter, Inc.).  The
manufacturer-recommended cutoffs for myocardial injury
were set at 0.5 ng/mL for Opus Magnum and 0.15 ng/mL
for ACCESS. The range of testing was 0.5–150 ng/mL for
Opus Magnum and 0–30.0 ng/mL for ACCESS.
In vivo studies
Study population
We did two in vivo studies. In the first study, we tested
whether the coronary angiography and angioplasty had
caused damage to the myocardium by checking the cTnI
level on the Opus Magnum system before and after the
procedure. We found unusually high cTnI concentrations.
To confirm whether the contrast media had positively
interfered with the cTnI immunoassay results, in the second
in vivo study, we used both the Opus Magnum and ACCESS
systems.
In the first in vivo study, we enrolled 45 patients scheduled
to receive coronary angiography with or without coronary
intervention. Of these patients, 14 received coronary
intervention. Eighty percent of the 45 patients were men.
The mean age was 57.9 years (range 22–75 years). Patients
with suspected acute coronary syndrome or renal function
impairment (serum creatinine > 1.5 mg/dL) were excluded.
In the second in vivo study, we enrolled 25 patients. Inclusion
and exclusion criteria were the same. Informed consent
forms were signed by all the participants.
Coronary angiography and blood sample collection
The contrast medium used for the coronary angiography
was iopromide (Ultravist; Schering). In the first in vivo
study, 5 mL of blood was collected in clot activator tubes
(serum separation tubes) immediately before the procedure
and at 5 minutes, 30 minutes, 60 minutes, and 6 hours after
the procedure. In the second in vivo study, blood samples
were collected immediately before, and at 5 minutes and 30
minutes after the procedure. All blood samples were drawn
from the sidearm of the femoral arterial sheath.
Approximately 20 minutes after being collected, specimens
were centrifuged at 3000 g (KUBOTA 2700) for 5 minutes.
The serum was then immediately analyzed or frozen and
thawed just before analysis. For the Opus Magnum
immunoassay, 40 +L of serum was used and, for the ACCESS
assay, 50 +L. All cTnI concentrations were tested in duplicate.
In vitro studies
The first in vitro study was done to observe whether different
contrast media could positively interfere with cTnI
immunoassay results. For both immunoassays, 12 different
contrast media were used as substrates. For each test the
specimen amount was 50 +L for the ACCESS assay and 40
+L for the Opus Magnum assay. The contrast media we
tested were iothalamate (Conray60; Mallinckrodt), ioversol
(Optiray320; Mallinckrodt), iohexol (Omnipaque300/350;
NycoMed), diatrizoate sodium (Hypaque76; Sanofi
Winthrop), diatrizoate methylglutamine (Angiografin60;
Schering), gadopenetic acid (Magnevist; Schering),
megluminamidotizoate (Urografin76; Schering), iopromide
(Ultravist300/370; Schering), iodipamide (Biligrafin;
Schering), and iodized ethylesters of poppy-seed oil
(Lipiodol; Guebert). In addition, one sample of serum
from a patient with acute myocardial infarction (AMI)
was used as the positive control. All tests were performed
in triplicate.
The second in vitro study was done to measure the effect
of contrast media concentration on cTnI immunoassay
results. This was done by mixing 0, 0.1, 0.2, 0.3, or 0.4 mL of
Ultravist370 with 5 mL of whole blood from the same
patient. The mixtures were centrifuged at 3000 g for 5
minutes, and then 40 +L of serum was pipetted for each
Opus Magnum assay and 50 +L of serum for each ACCESS
assay. One specimen from a patient with AMI was used as
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the positive control. All tests were performed in triplicate.
The reported cTnI concentration was the average of the
three tests.
Statistics
The paired Student’s t-test was used to determine the
difference between cTnI values of samples taken at different
times. The difference between the Opus Magnum and
ACCESS immunoassay systems was analyzed by unpaired
t-test. Wilcoxon signed-rank test was used to determine the
difference in the cTnI values collected from patients
undergoing coronary angiography and percutaneous
coronary intervention. A two-tailed p < 0.05 was considered
statistically significant. All analyses were done on SPSS 11.
RESULTS
In the first in vivo study, the baseline cTnI concentration
was lower than the cutoff value in all of the 45 patients
before the angiography. At 5 minutes after the procedure,
this value was found by Opus Magnum assay to be elevated
(mean 19.68 ng/mL; range 1.41–86.1 ng/mL) in 84% of the
patients (n = 38). At 30 minutes after the procedure, the cTnI
concentration had declined, with only 8.9% of the patients
(n = 4) showing concentrations above the cutoff value
(mean 9.45 ng/mL; range 2.83–18.5 ng/mL). The cTnI
concentrations measured at these two times were
significantly different (p < 0.00001). The cTnI concentration
at 1 and 6 hours after angiography were both below the
cutoff in all the 45 patients (Figure 1). The mean cTnI
concentration at 5 minutes was higher in patients undergoing
coronary intervention than in those undergoing diagnostic
angiography only (27.2 vs 11.9 ng/mL; p = 0.0385). In the
second in vivo study, we compared Opus Magnum and
ACCESS estimated cTnI concentrations in samples taken
from 25 patients. Unlike the results obtained by the Opus
Magnum system, all ACCESS estimated cTnI concentrations
were below the cutoff value of 0.15 ng/mL. There was no
significant change in ACCESS estimated cTnI values of
samples taken at 5 minutes and at 30 minutes, when
comparing those values with baseline values (p = 0.498 and
p = 0.107, respectively). The Opus Magnum estimated cTnI
values, however, were found to have risen significantly at
5 minutes and 30 minutes, when compared with baseline
values (p = 0.001 and p = 0.002, respectively). Of this patient
group, 84% (21 patients) had elevated cTnI concentrations,
as measured by the Opus Magnum system (Table 1). Opus
Magnum estimated cTnI values at 5 minutes and 30 minutes
were significantly different from those estimated by ACCESS
at the same sample collection times (p = 0.001 and p = 0.04,
respectively).
In the first in vitro study, we found that use of almost
all of the contrast media resulted in a positive reaction for
cTnI in the Opus Magnum assay. An average value was
13.1 ng/mL, and the maximum was found in the test using
iodized ethylesters of poppy-seed oil, which had a value of
34.6 ng/mL. However, when using the ACCESS assay,
iodized ethylesters of poppy-seed oil was the only contrast
medium that produced a positive cTnI reaction (Table 2).
In the second in vitro study, in which we observed the
effect of different concentrations of a contrast medium, both
assays found the cTnI levels in pure serum to be below
cutoff values. The cTnI concentration in the positive control
serum, which came from a patient with AMI, was found by
Opus Magnum to be 24.05 ng/mL and by ACCESS assay to
be 23.93 ng/mL. When using the Opus Magnum assay to
measure cTnI concentrations in the samples with different
contrast medium-to-blood ratios (2–8%), we found that all
concentrations were higher than the cutoff. The higher the
ratio of contrast mixture to blood, the higher the estimated
cTnI concentration. However, when the ACCESS assay was
used to check the same specimens, the cTnI concentrations
were found to be below the cutoff value (Table 3).
Figure 1. The decay in the concentrations of cardiac troponin I (cTnI) by
Opus Magnum assay in the in vivo study. Opus Magnum cTnI values
declined significantly at 30 minutes compared with values at 5 minutes
after coronary angiography. *p < 0.00001.
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DISCUSSION
This study found that most contrast media can potentially
lead to false-positive cTnI results in the Opus Magnum
assays. Iodized ethylesters of poppy-seed oil can
cause false-positive results in both assays. False-positive
results can be observed up to 1 hour after coronary
angiography.
Immunoassays use an array of mammalian antibodies,
either monoclonal (mouse) or polyclonal (goat, sheep,
rabbit). The Opus Magnum assay uses a fluorescence
enzyme immunoassay as the test module. In one study,
two different goat antibodies were used in the Opus
Magnum’s sandwich format [7]. One polyclonal antibody
was in solid phase and bound to cTnI in the sample, and
the other conjugated polyclonal antibody, which was
coupled to fluorescence as a signal transducer, was detected
after the antigen binding and the separation of the bound
Table 2. The cTnI assay results of 12 contrast media and
one positive control serum
Contrast media
cTnI by Opus cTnI by
Magnum, ng/mL ACCESS, ng/mL
Conray60 11.30 0
Optiray320 11.10 0
Omnipaque300 12.90 0
Omnipaque350 14.60 0
Hypaque76 10.00 0
Angiografin60 7.47 0
Magnevist 10.90 0
Urografin76 8.44 0
Ultravist300 13.20 0
Ultravist370 12.90 0
Biligrafin 9.55 0
Lipiodol 34.60 0.54
Positive control 24.08 24.00
cTnI = cardiac troponin I.
Table 1. Results of 25 patients’ cTnI by Opus Magnum and ACCESS systems
Opus Magnum system, ng/mL ACCESS system, ng/mL
Before CAG 5 minutes 30 minutes Before CAG 5 minutes 30 minutes
after CAG after CAG after CAG after CAG
1 < 0.5 42.0 22.0 0.013 0.016 0.015
2 < 0.5 8.9 < 0.5 0.022 0.007 0.021
3 < 0.5 50.0 < 0.5 0.016 0.038 0.037
4 < 0.5 17.58 4.8 0.001 0.069 0.066
5 < 0.5 2.5 < 0.5 0.016 0.038 0.027
6 < 0.5 3.53 < 0.5 0.044 0.050 0.061
7 < 0.5 3.5 < 0.5 0.018 0.029 0.062
8 < 0.5 19.6 < 0.5 0.021 0.016 0.016
9 < 0.5 < 0.5 < 0.5 0.033 0.032 0.026
10 < 0.5 8.02 < 0.5 0.028 0.037 0.074
11 < 0.5 < 0.5 < 0.5 0.029 0.036 0.029
12 < 0.5 < 0.5 < 0.5 0.011 0.011 0.015
13 < 0.5 15.0 < 0.5 0.034 0.025 0.035
14 < 0.5 49.5 37.3 0.022 0.050 0.014
15 < 0.5 45.0 25.0 0.021 0.015 0.025
16 < 0.5 3.48 < 0.5 0.016 0.011 0.014
17 < 0.5 0.55 < 0.5 0.001 0.001 0.082
18 < 0.5 48.6 < 0.5 0.021 0.012 0.038
19 < 0.5 1.16 0.784 0.024 0.021 0.022
20 < 0.5 1.59 1.46 0.069 0.046 0.024
21 < 0.5 1.03 0.711 0.014 0.006 0.016
22 < 0.5 1.02 < 0.5 0.025 0.019 0.021
23 < 0.5 < 0.5 < 0.5 0.026 0.011 0.033
24 < 0.5 0.639 0.688 0.031 0.009 0.039
25 < 0.5 8.7 0.858 0.111 0.127 0.111
CAG = coronary angiography.
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form from the unbound form. The lack of binding specificity
of reagent antibodies in either of the two reactions was
found to cause interference [8]. The ACCESS cTnI assay is
also a two-site immunoenzymatic (sandwich) immunoassay.
All reagent antibodies in ACCESS are mouse monoclonal
antibodies [9]. There may be an unidentified antigenic site on
the contrast medium molecule for the reagents of polyclonal
or monoclonal antibodies in the cTnI immunoassays.
The difference in specificity between polyclonal and
monoclonal antibodies may partly explain the higher
prevalence of interference in the Opus Magnum assay than
in the ACCESS assay.
cTnI is a new generation of cardiac markers and is
generally accepted as a reliable tool for the diagnosis of
AMI and for determination of risk for patients with acute
coronary syndrome. However, cTnI may be increased in
conditions other than cardiac injury. High cTnI values
have been observed among patients with chronic renal
failure or skeletal muscle damage [8]. In addition, several
factors have been found to interfere with cTnI assay results.
These include hemolysis, bilirubin, lipid, autoantibodies,
heterophilic antibodies, rheumatoid factors, human anti-
mouse antibodies, and heparin [4–6,10]. Negative
interference factors have been less frequently reported.
Hemodilution by fluid therapy [11], the presence of fibrin
after incomplete separation of serum, circulating cTnI
autoantibodies, bilirubin, hemoglobin, as well as some
unidentified components in the blood of either healthy
subjects or patients with acute coronary syndrome have
all been reported to cause false-negative or falsely low
results in certain cTnI assays [12]. We know of no study
that has reported interference of contrast media with
cTnI immunoassay results. Our in vivo study found false-
positive cTnI results in 84% of our patients receiving
coronary angiography when the Opus Magnum system
was used.
Table 3. cTnI concentration in six samples with the Ultravist370 blood mixtures
Tube number
Ultravist370/blood cTnI by Opus Magnum, cTnI by ACCESS,
volume ratio, % ng/mL ng/mL
1 0 < 0.5 0
2 2.0 4.32 0
3 4.0 4.44 0
4 6.0 4.53 0
5 8.0 7.72 0
6 Positive control 24.05 23.93
cTnI = cardiac troponin I.
Because of the rapid development of interventional
cardiology, early coronary intervention is gradually
becoming more common in the treatment of patients with
acute coronary syndrome. Furthermore, in hospitals that
are sufficiently equipped, primary coronary intervention is
becoming a standard method of gaining reperfusion for
patients with AMI. cTnI is used as a marker of cardiac injury
after percutaneous coronary intervention. In this kind of
intervention, the use of contrast media is essential. In our in
vivo study, the potential interference of contrast media on
assays for cTnI was stronger in patients receiving coronary
intervention than in patients receiving coronary angiography
alone. This result might be the consequence of the larger
amounts of contrast media used. In any case, it is important
for clinicians to recognize that many factors, including
contrast media, can cause false-positive cTnI immunoassay
results. The positive interference caused by contrast media
in patients with normal renal function lasted for only 30
minutes in this study. In patients with some renal function
impairment, it is possible that the positive interference can
last longer than 30 minutes [13]. If cTnI levels are checked
after a percutaneous coronary intervention or coronary
angiography, the timing of the blood sampling is important.
The interference by the contrast media can effectively be
avoided if samples are collected 1 hour or longer after
coronary angiography in patients with normal renal
function. Such interference can be avoided in this way, even
with a cTnI immunoassay such as Opus Magnum.
We used heparin at the beginning of coronary
angiography, and a supplemental dose was usually needed
during coronary intervention. The effect of heparin on cTnI
has been investigated in several studies. The concentrations
of troponin measured in heparin-treated plasma are
markedly lower than in serum [14]. Therefore, the influence
of heparin on the positive interference of contrast media on
assay for troponin warrants further investigation.
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There are several limitations in this study. First, the
amount of contrast media used for each patient was
incompletely recorded, so the actual correlation of
interference and the volume of contrast media cannot be
determined in this in vivo study. Second, the blood
concentration of contrast media at 30 and 60 minutes after
administration was not checked, so its effect on the
magnitude of interference is uncertain.
CONCLUSIONS
The positive interference from various contrast media in
cTnI immunoassays should be taken into consideration
when interpreting cTnI values, especially when the blood
samples are obtained within the first hour of angiography.
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